BioCorRx Inc
Change company Symbol lookup
Select an option...
BICX BioCorRx Inc
BCH Banco de Chile
NLRCF Northern Lights Resources Corp
ABM ABM Industries Inc
LVOXW LiveVox Holding Equity Warrants Exp 18 June 2026 *W EXP 06/18/2026
TY- Tri-Continental Corp
BAC Bank of America Corp
KLXE KLX Energy Services Holdings Inc
OBNK Origin Bancorp Inc
SNDR Schneider National Inc
Go

Company profile

BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders. The Company's BioCorRx Recovery Program is a non-addictive, medication-assisted treatment (MAT) program for substance abuse that includes peer recovery support. The UnCraveRx Weight Loss Management Program is a medically assisted weight management program that is combined with a virtual platform application. It is also engaged in the research and development of sustained release naltrexone products for the treatment of addiction and other possible disorders. Its products include BICX101 and BICX104. Its lead candidate, BICX101, is a sustained release, injectable naltrexone for the treatment of opioid abuse and alcoholism. It is also developing an implantable naltrexone treatment, BICX104, a long-acting naltrexone implant that can last several months for the treatment of opioid dependence and alcohol use disorders. Its subsidiary is BioCorRx Pharmaceuticals, Inc.

Closing Price
$2.45
Day's Change
-0.05 (-2.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.45
Day's Low
2.43
Volume
(Light)
Volume:
457

10-day average volume:
2,743
457

Company Profile

BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders. The Company's BioCorRx Recovery Program is a non-addictive, medication-assisted treatment (MAT) program for substance abuse that includes peer recovery support. The UnCraveRx Weight Loss Management Program is a medically assisted weight management program that is combined with a virtual platform application. It is also engaged in the research and development of sustained release naltrexone products for the treatment of addiction and other possible disorders. Its products include BICX101 and BICX104. Its lead candidate, BICX101, is a sustained release, injectable naltrexone for the treatment of opioid abuse and alcoholism. It is also developing an implantable naltrexone treatment, BICX104, a long-acting naltrexone implant that can last several months for the treatment of opioid dependence and alcohol use disorders. Its subsidiary is BioCorRx Pharmaceuticals, Inc.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
290.49x
Price/Book (MRQ)
--
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

No short interest available.

Share Information

BICX is in a share class of common stock
Float
2.5M
Shares Outstanding
7.0M
Institutions Holding Shares
0
0.00%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Brady J. GranierCEO
  • Lourdes FelixPres.
  • Thomas Patrick WelchExec.VP
  • Kent Emry
  • Joseph J. Galligan

Address

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.